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ABSTRACT - The authors describe the case of a young Brazilian woman who was treated of ileocolonic Crohn’s disease
sparing rectum, as confirmed by colonoscopy and histopathological examination. After a 4-year course of sulfasalazine
treatment, she presented with skin facial lesions in vespertilio, fever, arthralgias and high titers of anti-ANA and LE cells.
A sulfasalazine-induced lupus syndrome was diagnosed, because after sulfasalazine withdrawal and a short course of
prednisone, the clinical symptoms disappeared and the laboratory tests returned to normal. Mesalazine 3 g/day was
started and the patient remained well for the next 3 years, when she was again admitted with fever, weakness, arthralgias,
diplopy, strabismus and hypoaesthesia in both hands and feet, microhematuria, haematic casts, hypocomplementemia and
high titers of autoimmune antibodies. A diagnosis of associated systemic lupus erythematosus was made. Although a
pulsotherapy with methylprednisolone was started, no improvement was noticed. A cyclophosphamide trial was tried and
again no positive results occurred. The patient evolved to severe clinical manifestations of general vasculitis affecting the
central and peripheral nervous system and lungs, having a fatal evolution after 2 weeks. Although uncommon, the
association of both disease may occur, and the authors call attention to this possibility, making a brief review of literature.
HEADINGS - Crohn disease. Lupus erythematosus, systemic.
+ Division of Gastroenterology, Department of Medicine, Juiz de Fora University, School of Medicine, Juiz de Fora, MG, Brazil.
* Professor of Gastroenterology, Juiz de Fora University, School of Medicine, Juiz de Fora, MG, Brazil.
** Fellowship of Division of Gastroenterology, Department of Medicine, Juiz de Fora University, School of Medicine.
Address of correspondence: Dr. Pedro Duarte Gaburri - Rua São Sebastião, 1050/301 - 36015-410 - Juiz de Fora, MG, Brazil. e-mail: pgaburri@artnet.com.br
INTRODUCTION
Crohn’s disease (CD) and systemic lupus erythematosus
(SLE) have been described in a rare association(3). Both disease
have ethiopathogenesis not well known, but the more accepted
theory for explanation is based in the interaction of
environmental agents and immunological responses in a host
genetically susceptible(4). Sometimes the differentiation of
intestinal lesions of CD from SLE is not easy. Gastrointestinal
symptoms, laboratory studies, and radiographic findings may
appear very similar in both diseases. However, the association
of both diseases in a same patient it is not common. We
report a patient, who developed a SLE with fatal evolution
after 7 years of treatment for ileocolonic CD.
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CASE REPORT
A 24-year old Brazilian woman presented, in March 1992, with
diarrhea, weight loss and abdominal pain. She had perineal and
vaginal fistulae. A colonoscopy showed longitudinal scattered ulcers
and erosions from ileum to descending colon. The hystopathological
examination of samples of ileum and colonic mucosa demonstrated
cryptitis and noncaseating granulomas. She was considered to have
CD and sulfasalazine 3 g/day plus metronidazol 15 mg/kg/day were
started. A clinical remission was achieved with healing of fistulae,
gain of weight and relief of abdominal pain. After 6 months only
sulfasalazine was being employed. She felt well for 4 years. In
April 1996 she developed a “lupus-like syndrome”, with skin facial
lesions in “vespertilio”, arthralgias and fever. High titers of
autoimmune antibodies (anti-ANA) and LE cells were demonstrated
in laboratory researches. She was considered to have a sulfasalazine-
induced lupus syndrome and mesalazine 1.6 g/day was introduced
in treatment after sulfasalazine withdrawal. A complete remission
of all clinical and laboratory manifestations was observed and the
patient became well for the next 3 years. She was admitted again in
February 1999, with perineal fistula, fever (39 ºC), arthralgias,
weakness, strabismus, and hipoaestesia in the feet and both hands.
The laboratory tests showed hypocomplementemia, and high titers
of anti-ANA (1:320) and anti-Ro (SS-A) antibody positive, while
the anti-histone antibody was negative. Urinalysis demonstrated
proteinuria, microhaematuria and haematic casts. The hipoaestesia
progressed to anesthesia and paraparesia of upper and lower limbs.
The study of cranium and medullae through a CT scan and a MNR
did not show any abnormalities. The liquor was clear with a normal
protein concentration and cell count, and negative bacterioscopy
analysis and culture. The above findings are in according with the
American College of Rheumathology criteria for the diagnosis of
SLE(10).
A pulsotherapy with methylprednisolone was started. No signs
of improvement were noticed and a cyclophosphamide trial was tried
without any response. She became tetraplegic. A severe respiratory
failure occurred in the 8th day and an assisted ventilatory support
was introduced. No improvement was observed and she died on the
15th day.
DISCUSSION
SLE is a multisystemic autoimmune disease with protean clinical
presentations as a result of widespread inflammation and immune complex
deposition. During evolution of SLE, gastrointestinal symptoms occur
in approximately 50% of patients(5). Virtually any gastrointestinal tissue
can be involved, most often as a result of SLE vasculopathy.
Although it remains unclear whether CD is autoimmune in nature,
perinuclear staining antineuthrophil cytoplasmic antibodies (p-
ANCA), known to be associated with vasculitis and tissue injury by
activating leukocytes, occur near 15% of the cases, while remission
of the disease, in the presence of HIV-infection and exacerbation,
after treatment with interleukin-2, have been reported(6, 9).
Several case reports have indicated that differentiation of CD
from SLE may be difficult. Gastrointestinal symptoms, laboratory
studies, and radiographic findings may have similar features in both
diseases(1). Moreover, the SLE syndrome has been described in patients
with CD after sulfasalazine(2) as well as mesalazine treatment(11).
Curiously, acute leukocytoclastic vasculitis of skin has been described
in CD with the same characteristics of autoimmune diseases(12).
However, coexistence of SLE and CD has been rarely described(3, 7, 8).
In all these clinical situations the correct diagnosis has important
treatment and prognostic implications. In our case, the biopsy
specimens from the ileal and colonic mucosa showed cryptitis and
non-caseating granuloma with no ischemic changes or vasculitis. After
7-years of well-controlled CD with medical treatment, the patient
developed complex systemic manifestations, with hypocom-
plementemia, high titers of anti-ANA and anti-Ro (SS-A) antibody
positive. Proteinuria, microhaematuria and haematic casts were found
in urinalysis. These findings are in according with SLE diagnosis. The
anti-histone antibody negative makes the hypothesis of drug-induced
lupus syndrome improbable(11). Based on these facts, we believe that
our patient could accurately be diagnosed as having idiophatic SLE
with CD.
In conclusion, although some of the systemic complications of these
diseases may overlap, both diseases may occur as primary disorders.
Coexistence of SLE in patients with inflammatory bowel diseases, should
be considered when complex extraintestinal manifestations are present,
especially when autoimmune-antibodies are detected.
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RESUMO - Descrição do caso de uma mulher jovem, brasileira, que foi tratada de doença de Crohn acometendo íleo e cólon, poupando o
reto, e confirmada por colonoscopia e estudo histopatológico. Após 4 anos de tratamento com sulfasalazina, apresentou lesões faciais em
vespertilio, febre, artralgia e altos títulos de anticorpo anti-nuclear e células LE. Uma síndrome lúpica induzida pela sulfasalazina foi
diagnosticada, porque após a retirada desta e um curto período de administração de prednisona, os sintomas clínicos desapareceram e
os testes laboratoriais retornaram ao normal. Mesalazina 3 g/dia foi iniciada e a paciente manteve-se bem pelos próximos 3 anos,
quando foi novamente admitida com febre, adinamia, artralgias, diplopia, estrabismo e hipoestesia em ambas as mãos e pés,
microhematuria, cilindros hemáticos, hipocomplementemia e altos títulos de anticorpos auto-imunes. Diagnóstico de lupus eritematoso
sistêmico foi realizado. Embora uma pulsoterapia com metilpredinisolona tenha sido iniciada, nenhuma melhora foi observada. Um ciclo
com ciclofosfamida foi tentado e novamente nenhum resultado positivo foi alcançado. A paciente apresentou quadro de manifestações
clínicas graves de vasculite generalizada, afetando o sistema nervoso central e periférico e os pulmões, evoluindo para o óbito em duas
semanas. Embora incomum, a associação entre as duas doenças pode ocorrer e é destacada esta possibilidade, com uma breve revisão
da literatura.
DESCRITORES - Doença de Crohn. Lupus eritematoso sistêmico.
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